The patient of latent TB does not show any kind of symptoms even when they are infected by M. tuberculosis. Also, the person suffering from latent TB does not spread the disease. Majorly, tuberculin skin test or TB blood test are recommended for the diagnosis of latent TB infection.
QIAGEN and F. Hoffmann La-Roche Ltd. – Notable Market Players in Latent TB Detection Market
The latent TB detection market majorly consists of the players such QIAGEN, BioMeriux S.A., F. Hoffmann La-Roche Ltd., BD, ARKRAY, Inc., Abbott, Serum Institute of India Pvt. Ltd, Oxford Immunotec Ltd, Lionex GmbH among others. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have adopted several inorganic and organic strategies to accelerate their growth and improve their market position.
Below is the list of the growth strategies done by the players operating in the latent TB detection market:
| Year | News |
| July, 2018 | Oxford Immunotec launched CE-marked T-Cell Select kit in Europe. This will simplify workflow, improve throughput, and reduce labor costs in performing the T-SPOT.TB test. |
| October, 2019 | Serum Institute of India Pvt. Ltd developed a new test for diagnosing TB (C-Tb). SSI has entered into a partnership with Serum Institute of India Pvt. Ltd. SIIPL be manufacturing and distributing the test and the production will take place at SIIPL’s facilities in Pune, India. |
| September, 2020 | Oxford Immunotec received approval from the FDA to allow use of the T-SPOT.TB test in two years of age and older. This will help in meeting the pediatric patients needs for TB management. |
